Showing 6531-6540 of 10602 results for "".
- Topical PDE4 Inhibitor from Arcutis Shows Benefit in Seborrheic Dermatitishttps://practicaldermatology.com/news/topical-pde4-inhibitor-from-arcutis-shows-benefit-in-seborrheic-dermatitis/2460544/Positive topline data from a Phase 2 clinical trial suggest ARQ-154 (topical roflumilast foam) from Arcutis Biotherapeutics, Inc. is a potential treatment for seborrheic dermatitis. Study results show that roflumilast foam 0.3%
- Suneva to Market and Distribute Neauvia's Plasma IQ in North Americahttps://practicaldermatology.com/news/suneva-to-market-and-distribute-neauvias-plasma-iq-in-north-america/2460534/Suneva Medical, Inc., will market and distribute Neauvia Plasma IQ throughout North America as part of a new partnership. The first Class 2 FDA-cleared plasma energy device, Plasma IQ delivers focused, controlled plasma energy to create microinjuries on the skin, renewing
- First Patient Enrolled in AVITA Therapeutic’s Pivotal Study of RECELL System for Vitiligohttps://practicaldermatology.com/news/first-patient-enrolled-in-avita-therapeutics-pivotal-study-of-recell-system-for-vitiligo/2460528/AVITA Therapeutics, Inc. a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs initiated its pivotal study assessing the use of the RECELL System to treat stable vitiligo with th
- Call for Entries: Sanofi Genzyme and Regeneron Launches 2020 ‘Agents of Change’ AD Challengehttps://practicaldermatology.com/news/call-for-entries-sanofi-genzyme-and-regeneron-launches-2020-agents-of-change-ad-challenge/2460527/In recognition World Atopic Dermatitis (AD) Day, Sanofi Genzyme and Regeneron are launching the 2020 ‘Agents of Change’ AD Challenge, a
- New Allergan Aesthetics and Skinbetter Initiative Aims to Advance Health Equity and Diversity in Aestheticshttps://practicaldermatology.com/news/new-initiative-allergan-aesthetics-and-skinbetter-aims-to-advance-health-equity-and-diversity-in-aesthetics/2460526/Allergan Aesthetics, an AbbVie company, and Skinbetter Science have launched a new long-term, educational initiative—DREAM: Driving Racial Equity in Aesthetic Medicine—to further the principles of racial and ethnic diversity, inclusion, respect and understanding in the fields of derma
- Partner Therapeutics Moves Ahead with Phase 3 Study of Leukine Plus Ipilumimab and Nivolumab for Melanomahttps://practicaldermatology.com/news/partner-therapeutics-moves-ahead-with-phase-3-study-of-leukine-plus-ipilumimab-and-nivolumab-for-melanoma/2460524/Partner Therapeutics, Inc. is resuming enrollment in the National Cancer Institute (NCI)-sponsored ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) study of Leukine plus Ipilumimab and Nivolumab for Melanoma following a successful planned interim analysis. EA6141 (
- Medicine X Launches Eczema Xplained Patient Story To Drive Understanding and Awareness of ADhttps://practicaldermatology.com/news/medicine-x-launches-eczema-xplained-patient-story-to-drive-understanding-and-awareness-of-ad/2460519/Medicine X today is launching Eczema Xplained, its first illustrated story in the U.S. on atopic dermatitis, the most comm
- Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areatahttps://practicaldermatology.com/news/arena-pharmaceuticals-announces-first-subject-dosed-in-phase-2-trial-evaluating-etrasimod-in-alopecia-areata/2460515/The first subject has been dosed in
- Skin Diseases Highly Common in Older Adultshttps://practicaldermatology.com/news/skin-diseases-highly-common-in-older-adults/2460507/Fully 80 percent of adults aged 70 to 93 have at least one skin disease that required treatment, and the most common conditions were fungal skin infections, rosacea, actinic keratosis, and eczema, according to a new study in the 
- Estée Lauder Companies and Atropos Therapeutics Partner to Discover Botanical Senomodulatorshttps://practicaldermatology.com/news/estee-lauder-companies-and-atropos-therapeutics-partner-to-discover-senomodulators/2460500/The Estée Lauder Companies and Atropos Therapeutics are joining forces to discover botanical senomodulators or senescence-modulating chemicals. Atropos Therapeutics Inc. has a proprietary platform to identify and develop senescence-modu